Join Growin Stock Community!

宣捷幹細胞4724.TW Overview

TW StockBiotech. & Medical
(No presentation for 4724)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

宣捷幹細胞（4724）Overall Performance

宣捷幹細胞（4724）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

宣捷幹細胞（4724） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

宣捷幹細胞（4724）Key Information

宣捷幹細胞（4724）Profile

Meribank Biotech Co., Ltd manufactures, develops, and stores mesenchymal stem cells in Taiwan. The company engages in storage of placental umbilical cord mesenchymal stem cells, cord blood hematopoietic stem cells, and immune cells. It is also involved in cell cryopreservation protocol and postpartum nursing services. Meribank Biotech Co., Ltd was founded in 2013 and is based in Taipei City, Taiwan.

宣捷幹細胞（4724）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

No related data records

default symbol

4724

宣捷幹細胞

14.60D

-2.74%

(-0.03)

  • When is 4724's latest earnings report released?

    The most recent financial report for 宣捷幹細胞 (4724) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4724's short-term business performance and financial health. For the latest updates on 4724's earnings releases, visit this page regularly.

  • What is the operating profit of 4724?

    According to the latest financial report, 宣捷幹細胞 (4724) reported an Operating Profit of -12.42M with an Operating Margin of -4.96% this period, representing a growth of 73.55% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4724's revenue growth?

    In the latest financial report, 宣捷幹細胞 (4724) announced revenue of 250.42M, with a Year-Over-Year growth rate of 92.14%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4724 have?

    At the end of the period, 宣捷幹細胞 (4724) held Total Cash and Cash Equivalents of 136.2M, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4724 go with three margins increasing?

    In the latest report, 宣捷幹細胞 (4724) did not achieve the “three margins increasing” benchmark, with a gross margin of 46.43%%, operating margin of -4.96%%, and net margin of -7.73%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4724's profit trajectory and future growth potential.

  • Is 4724's EPS continuing to grow?

    According to the past four quarterly reports, 宣捷幹細胞 (4724)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4724?

    宣捷幹細胞 (4724)'s Free Cash Flow (FCF) for the period is 81.6M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 298.37% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.